Diagnosis and Treatment of MS in Patients Suffering from Various Degrees of the Disease with a Clinical Approach: The Orginal Article

Authors

  • Hossein Tahernia
  • Fatemeh Esnaasharieh
  • Hadis Amani
  • Maryam Milanifard
  • Fariba Mirakhori

DOI:

https://doi.org/10.47750/pnr.2022.13.S01.227

Keywords:

MS, Clinical Approach, Genetic Factors, Autoimmune Disease.

Abstract

This study Orginal investigated the diagnosis and treatment of MS in patients (111 Patients) with various degrees of the disease with a clinical approach. MS is an autoimmune disease in which the body's immune system attacks its own tissues. In MS, the malfunctioning immune system destroys myelin. Myelin is a fatty substance that covers and protects the nerve fibers of the brain and spinal cord. When the protective myelin sheath is damaged and nerve fibers are exposed, the speed at which messages are transmitted along the nerve slows or is blocked. The concordance rate for MS in monozygotic identical twins is only 20-35%, indicating that genetic factors have only a moderate effect and transmission is not 100%. The presence of non-Mendelian predisposing factors along with environmental effects plays an important role. For first-degree family members of people with MS, the risk of developing the disorder is seven times greater than in the general population, but the excess family risk for the disease is only 2.5-5%. Research on single nucleotide polymorphisms that play a role in the risk of developing severe disease or developing certain types of MS is ongoing. To date, however, HLA-DRB1 is the only chromosomal locus consistently associated with MS susceptibility. Molecular mimicry has been proposed as an etiological process in MS. The molecular mimicry hypothesis suggests that T cells in peripheral blood may, after being activated to attack a foreign antigen, then mistakenly continue to attack proteins in the brain that have similar epitopes.

Downloads

Published

2022-10-03

Issue

Section

Articles

How to Cite

Diagnosis and Treatment of MS in Patients Suffering from Various Degrees of the Disease with a Clinical Approach: The Orginal Article. (2022). Journal of Pharmaceutical Negative Results, 1908-1921. https://doi.org/10.47750/pnr.2022.13.S01.227